每经AI快讯,今日发布的2024年国家医保目录显示,百时美施贵宝三款创新药物纳入2024年国家医保目录,包括全球首个且目前唯一获批心肌肌球蛋白抑制剂迈凡妥(玛伐凯泰)胶囊用于治疗梗阻性肥厚型心肌病,全球首个且目前唯一获批口服TYK2变构抑制剂颂狄多(氘可来昔替尼片)用于治疗中重度斑块状银屑病,全球首个且目前唯一获批红细胞成熟剂利布洛泽(注射用罗特西普)用于治疗β-地中海贫血。 (文章来源:每日经济...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.